The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro

The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro

Anti-angiogenic agents, such as the multi-tyrosine kinase inhibitor sunitinib, are key first line therapies for metastatic clear cell renal cell carcinoma (ccRCC), but their mechanism of action is not fully understood. Here, we take steps towards validating a computational prediction based on differ...

Full description

Bibliographic Details
Main Authors: Rafia S. Al-Lamki, Nicholas J. Hudson, John R. Bradley, Anne Y. Warren, Tim Eisen, Sarah J. Welsh, Antony C. P. Riddick, Fiach C. O’Mahony, Arran Turnbull, Thomas Powles, SCOTRRCC Collaborative, Antonio Reverter, David J. Harrison, Grant D. Stewart
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Biology
Subjects:
renal cancer
kidney cancer
sunitinib
PHAX
organ culture
Online Access:https://www.mdpi.com/2079-7737/9/4/74

Internet

https://www.mdpi.com/2079-7737/9/4/74

Similar Items